1. Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes.
- Author
-
Siegmund T, Ampudia-Blasco FJ, and Schnell O
- Subjects
- Adult, Humans, Hypoglycemic Agents pharmacology, Male, Middle Aged, Sodium-Glucose Transporter 2 Inhibitors pharmacology, Diabetes Mellitus, Type 1 drug therapy, Hypoglycemic Agents therapeutic use, Sodium-Glucose Transporter 2 Inhibitors therapeutic use
- Abstract
Type 1 diabetes mellitus (T1DM) prevalence is increasing and despite all available modern treatment options, an overall small but noticeable increase of mean HbA1c was recently observed in various registries. Authorized adjunctive pharmacological treatment options to insulin therapy are still scarce for T1DM. In February 2019, the European Medicines Agency (EMA) approved dapagliflozin as first in class sodium/glucose co-transporter 2 inhibitor (SGLT-2i) adjunctive therapy to insulin in patients with T1DM, which is currently still not approved by the FDA in the United States. SGLT-2is have shown significant improvement in HbA1c, reducing body weight and increasing time-in-range by reducing glycaemic variability, as well as reductions in total daily insulin dose in the trials in persons with T1DM. The cases presented here translate some of the observations gained from clinical trials into a real-world environment. They demonstrate that even highly practised and educated patients can benefit from the addition of a SGLT-2i as adjunctive treatment to insulin in T1DM. In summary, these cases demonstrate that a variety of patients with T1DM in a real-world setting may benefit from SGLT-2i treatment, as they have the potential to improve HbA1c, excess of body weight and increasing TiR among other things., Competing Interests: Declaration of Competing Interest TS has acted as speaker for Abbott, Ascensia, Astra Zeneca, Bayer, Berlin Chemie, Biogen, Boehringer-Ingelheim, Eli Lilly, Medtronic, MSD, Novartis, Novo Nordisk, Roche, Sanofi; Participation in advisory boards: Abbott, Ascensia, Bayer Vital, Boehringer-Ingelheim, Eli Lilly, Janssen, Medtronic, MSD, Novo Nordisk, Roche/Eversense, Sanofi; Received scientific support from: Astra Zeneca/Bristol-Myers Squibb, Becton Dickinson, Eli Lilly, MSD, Novo Nordisk, Sanofi. FJAB has acted as a member of scientific advisory boards for AstraZeneca, Eli Lilly, Merck, Novo Nordisk, Sanofi; Ad hoc consulting for: Abbott Diabetes Care, Boehringer-Ingelheim, GlaxoSmithKline, LifeScan, MannKind Co., Medtronic, Menarini, Novartis; Speaking engagement for: Abbott Diabetes Care, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Life Scan, Eli Lilly, Madaus, Medtronic, Menarini, Merck, Novartis, Novo Nordisk, Sanofi; Research grant support from: Novo Nordisk, Sanofi. OS has acted as a member of advisory boards and given lectures for companies that are involved in glucose monitoring; and is CEO and founder of Sciarc GmbH., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF